Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Another Reckless FDA Action: Approval of Suvorexant (Belsomra)

Statement of Dr. Sammy Almashat, Researcher, Public Citizen’s Health Research Group

The U.S. Food and Drug Administration’s (FDA) decision to approve suvorexant (brand name: Belsomra) will surely worsen the public health crisis caused by the proliferation of dangerous and habit-forming sleep medications over the past two decades.

In addition to flying in the face of the FDA’s recent but belated attempts to mitigate the high numbers of deaths and injuries resulting from traffic accidents induced by these medications, Wednesday’s decision is troubling in its own right. The lowest doses of suvorexant were approved by the agency despite having never been tested in large clinical studies that are a standard requirement for all modern medication – and dosage – approvals, while the higher doses demonstrated only marginal benefits.

Like its predecessors, suvorexant was found to cause severe next-day driving impairment, prompting the FDA to caution patients against driving or engaging in other activities requiring “full mental alertness” the following morning.

However, for a medication indicated for daily and long-term use, this is an obviously unrealistic request and one that will unfortunately fail to prevent the inevitable harm to both patients and the public.

For more information, see Public Citizen’s May 2013 FDA advisory committee testimony and June 2013 letter to the FDA opposing the approval of suvorexant.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.